Oncotelic Therapeutics, Inc.
Oncotelic Therapeutics, Inc. (OTLC): 5 pipeline candidates. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
N/A
D/E 0.50 · 0% dilution
Lead: Phase 2
5 candidates
N/A
N/A
A transparent, data-derived signal for Oncotelic Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$22.2M
Cash
—
Quarterly Burn
$342K
Runway
—
Revenue
—
Pipeline (5 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Jun 2021Institutional holders
1
Total value held
$12K
| Holder | Shares | Value |
|---|---|---|
| ifp advisors, inc | 61,196 | $12K |
Frequently asked questions
How many drug candidates are in Oncotelic Therapeutics, Inc.'s pipeline?
Oncotelic Therapeutics, Inc. (OTLC) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Oncotelic Therapeutics, Inc.'s market capitalization?
Oncotelic Therapeutics, Inc.'s market capitalization is approximately $22.2M.
Who is the CEO of Oncotelic Therapeutics, Inc.?
Dr. Vuong Trieu Ph.D. is the chief executive officer of Oncotelic Therapeutics, Inc. (OTLC).
Get the full picture on Oncotelic Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.